Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131


Infrequent physician use of implantable cardioverter-defibrillators risks patient safety.

Lyman S, Sedrakyan A, Do H, Razzano R, Mushlin AI.

Heart. 2011 Oct;97(20):1655-60. doi: 10.1136/hrt.2011.226282. Epub 2011 Jul 27.


A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.


Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.

Marijon E, Trinquart L, Otmani A, Waintraub X, Kacet S, Clémenty J, Chatellier G, Le Heuzey JY; Evaluation Médico-Economique du Défibrillateur Automatique Implantable (EVADEF) Investigators.

Am Heart J. 2009 Feb;157(2):391-397.e1. doi: 10.1016/j.ahj.2008.09.023. Epub 2008 Dec 3.


The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.

Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM.

Ital Heart J. 2005 Mar;6(3):272-80.


[Spanish Implantable Cardioverter-Defibrillator Registry. Third Official Report of the Spanish Society of Cardiology Working Group on Implantable Cardioverter-Defibrillators (2006)].

Peinado R, Torrecilla EG, Ormaetxe J, Alvarez M; Grupo de Trabajo de Desfibrilador Implantable.

Rev Esp Cardiol. 2007 Dec;60(12):1290-301. Spanish.


Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors.

Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, Wiesfeld AC, Bakker PF, Robles de Medina EO.

Circulation. 1995 Apr 15;91(8):2195-203.


Differences in outcomes between patients treated with single- versus dual-chamber implantable cardioverter defibrillators: a substudy of the Multicenter Automatic Defibrillator Implantation Trial II.

Berenbom LD, Weiford BC, Vacek JL, Emert MP, Hall WJ, Andrews ML, McNitt S, Zareba W, Moss AJ.

Ann Noninvasive Electrocardiol. 2005 Oct;10(4):429-35.


Physician procedure volume and complications of cardioverter-defibrillator implantation.

Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA.

Circulation. 2012 Jan 3;125(1):57-64. doi: 10.1161/CIRCULATIONAHA.111.046995. Epub 2011 Nov 17.


Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator.

Curtis JP, Luebbert JJ, Wang Y, Rathore SS, Chen J, Heidenreich PA, Hammill SC, Lampert RI, Krumholz HM.

JAMA. 2009 Apr 22;301(16):1661-70. doi: 10.1001/jama.2009.547.


The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries.

Al-Khatib SM, Lucas FL, Jollis JG, Malenka DJ, Wennberg DE.

J Am Coll Cardiol. 2005 Oct 18;46(8):1536-40. Epub 2005 Sep 23. Erratum in: J Am Coll Cardiol. 2005 Nov 15;46(10):1964.


[Spanish registry of implantable cardioverter defibrillator. Second official report of the Spanish Society of Cardiology Working Group on Implantable Cardioverter Defibrillators (2005)].

Peinado R, Torrecilla EG, Ormaetxe J, Alvarez M; Spanish Society of Cardiology Working Group on Implantable Cardioverter Defibrillators.

Rev Esp Cardiol. 2006 Dec;59(12):1292-302. Spanish.


Implantable cardioverter defibrillators in Israel: utilization and implantation trends.

Greenberg D, Katz A, Epstein M, Golovchiner G, Ilia R, Caspi A.

Int J Cardiol. 2002 Jan;82(1):17-23.


[14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].

Vester EG, Dees H, Dobran I, Hennersdorf M, Perings C, Heydthausen M, Winter J, Strauer BE.

Z Kardiol. 2000;89 Suppl 3:194-205. German.


Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.

Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, Albert CM; TOVA Investigators.

Circulation. 2004 Mar 23;109(11):1386-91. Epub 2004 Mar 1.


Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.

Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, Brookhart MA, Winkelmayer WC.

Am J Kidney Dis. 2011 Sep;58(3):409-17. doi: 10.1053/j.ajkd.2011.03.026. Epub 2011 Jun 12. Erratum in: Am J Kidney Dis. 2012 Jun;59(6):895.


Use of implantable cardioverter defibrillators in the New Zealand context from 2000 to 2007.

Larsen PD, De Silva P, Harding SA, Woodcock E, Lever NA.

N Z Med J. 2010 Feb 19;123(1309):76-85.


Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).

Day JD, Doshi RN, Belott P, Birgersdotter-Green U, Behboodikhah M, Ott P, Glatter KA, Tobias S, Frumin H, Lee BK, Merillat J, Wiener I, Wang S, Grogin H, Chun S, Patrawalla R, Crandall B, Osborn JS, Weiss JP, Lappe DL, Neuman S.

Circulation. 2007 May 8;115(18):2382-9. Epub 2007 Apr 30.


A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study.

Dubner S, Valero E, Pesce R, Zuelgaray JG, Mateos JC, Filho SG, Reyes W, Garillo R.

Ann Noninvasive Electrocardiol. 2005 Oct;10(4):420-8.

Items per page

Supplemental Content

Write to the Help Desk